

## FOR IMMEDIATE RELEASE

### THERAPEUTICSMD TO HOST THIRD QUARTER 2013 EARNINGS CALL

Boca Raton, FL, October 21, 2013 – **TherapeuticsMD, Inc. (NYSE MKT: TXMD)** announced today it will release its third quarter 2013 financial results on Monday, November 4, 2013 at approximately 4:00 pm EST and will host a conference call shortly thereafter at approximately 4:30 pm EST to review the results. The call will be hosted by Robert Finizio, Co-Founder and Chief Executive Officer, and Dan Cartwright, Chief Financial Officer. Call in information follows:

Date	November 4, 2013
Time	4:30 pm EST
Telephone access: U.S. and Canada	800-619-2686
Telephone access: International	303-223-4363
Access code	21682427
Live webcast	<a href="http://www.therapeuticsmd.com">www.therapeuticsmd.com</a> (see Investor tab)

An audio replay will be available on-demand shortly after the completion of the call until November 18, 2013 at 11:59 pm EST at the aforementioned URL, or by dialing 800-633-8284 in the U.S. and Canada, or 402-977-9140 from abroad. The access code for all callers is 21682427.

#### **About TherapeuticsMD, Inc.**

TherapeuticsMD, Inc. is a women's healthcare company focused on developing and commercializing products targeted exclusively for women. We manufacture and distribute branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins and cosmetics, under our vitaMedMD® and BocaGreenMD™ brands. We are developing advanced hormone therapy pharmaceutical products that fill the critical and long-ignored need for better treatments in the hormone and women's health market. Our advanced hormone therapies are based on a novel technology that enables delivery of bio-identical hormones through a variety of dosage forms and administration routes. These bio-identical hormone therapies match the molecular structure of the estradiol and/or progesterone produced in the body. Current programs include the REPLENISH trial, a Phase 3 clinical study evaluating the safety and efficacy of our TX 12-001-HR 17β-estradiol and progesterone combination product candidate in reducing the symptoms of menopause. We are also evaluating various other potential indications for our hormone technology, including oral contraception, preterm birth, vulvar and vaginal atrophy, and premature ovarian failure. More information is available at the following websites: [www.therapeuticsmd.com](http://www.therapeuticsmd.com), [www.ReplenishTrial.com](http://www.ReplenishTrial.com), [www.vitamedmd.com](http://www.vitamedmd.com), [www.vitamedmdrx.com](http://www.vitamedmdrx.com), and [www.bocagreenmd.com](http://www.bocagreenmd.com).

vitaMedMD® and TherapeuticsMD® are registered trademarks and BocaGreenMD™ is a trademark of TherapeuticsMD, Inc.

#### Contacts:

TherapeuticsMD, Inc.  
Dan Cartwright, 561-961-1930  
Chief Financial Officer  
[Dan.Cartwright@TherapeuticsMD.com](mailto:Dan.Cartwright@TherapeuticsMD.com)

#### Investor Relations:

In-Site Communications, Inc.  
Lisa M. Wilson, 917-543-9932  
[lwilson@insitecony.com](mailto:lwilson@insitecony.com)